Abstract

PURPOSE: Immune-mediated seizures are rare but are increasingly recognized as an etiology of seizures resistant to anti-seizure medications (ASMs). Antibody Prevalence in Epilepsy 2 (APE2) and Response to Immunotherapy in Epilepsy 2 (RITE2) scores were developed recently to identify patients who may be seropositive for serum central nervous system (CNS) specific antibodies (Ab) and may benefit from immunotherapy (Dubey et al. 2018). The goal of this study was to apply APE2 and RITE2 scores to an independent cohort of patients with seizures secondary to autoimmune encephalitis (AE) and to further verify the sensitivity and specificity of the scores.PRINCIPAL RESULTS: We conducted a retrospective study at Stanford University Hospital between 2008 and 2021 and included patients who had acute seizures and AE using diagnostic criteria from Graus (n=34 definite AE, 10 probable AE, and 12 possible AE) (Graus et al. 2016). Patients were excluded if they did not have a serum Ab panel investigated or had alternate diagnoses (n=55). APE2 and RITE2 scores were calculated based on clinical and diagnostic data (n=56). Serum Ab were positive in 73% of patients, in which 63% cases carried CNS specific Ab. An APE2 score=4 had a sensitivity of 97% and specificity of 14% to predict a positive serum CNS specific Ab. A RITE2 score=7 had a sensitivity of 93% and specificity of 60% to predict seizure responsiveness to immunotherapy.CONCLUSION: APE2 and RITE2 scores had high sensitivities but low specificities to predict seropositivity and seizure responsiveness to immunotherapy in patients with autoimmune encephalitis with seizures.

View details for DOI 10.1016/j.yebeh.2024.109737

View details for PubMedID 38518672